Alexion Pharmaceuticals (ALXN) Gets a Buy Rating from Cowen & Co.


Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) today and set a price target of $163. The company’s shares opened today at $130.03.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.2% and a 56.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Vertex Pharmaceuticals, and Atara Biotherapeutics.

Currently, the analyst consensus on Alexion Pharmaceuticals is a Strong Buy with an average price target of $162.63, which is a 25.1% upside from current levels. In a report released today, Raymond James also maintained a Buy rating on the stock with a $177 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $144.91 and a one-year low of $102.10. Currently, Alexion Pharmaceuticals has an average volume of 1.26M.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts